Kim M, Jin M, Jeon MJ, Kim EY, et al. Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodinerefractory, progressive, differentiated thyroid carcinoma: Real-world outcomes in a multicenter retrospective cohort study. Thyroid 2022 Apr 20. doi: 10.1089/thy.2022.0054.
PMID: 35443825